{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:20:07Z","timestamp":1788391207252,"version":"build-2803163510"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.027","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"857-873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Oncology in Melanoma and Skin Cancer Surgery"],"prefix":"10.1016","volume":"40","author":[{"given":"Shoshana","family":"Levi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Bank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mullinax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2026.05.027_bib1","doi-asserted-by":"crossref","unstructured":"Yang AS, Chapman PB. The History and Future of Chemotherapy for Melanoma. 2009.","DOI":"10.1016\/j.hoc.2009.03.006"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.027_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.027_bib3","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. 2012.","DOI":"10.1186\/1479-5876-10-85"},{"key":"10.1016\/j.hoc.2026.05.027_bib4","doi-asserted-by":"crossref","unstructured":"Cantwell-Dorris ER, O\u2019Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Published online 2011.","DOI":"10.1158\/1535-7163.MCT-10-0799"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.027_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of Mutated, Activated BRAF in Metastatic Melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.027_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma","volume":"29","author":"Ribas","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2026.05.027_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.027_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors","volume":"28","author":"Kefford","year":"2010","journal-title":"J Clin Oncol"},{"issue":"abstr. LBA1-1","key":"10.1016\/j.hoc.2026.05.027_bib9","first-page":"1020","article-title":"BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E\/K) metastatic melanoma","volume":"24","author":"Trefzer","year":"2011","journal-title":"Pigment Cell Res"},{"issue":"9839","key":"10.1016\/j.hoc.2026.05.027_bib10","first-page":"380","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"7326","key":"10.1016\/j.hoc.2026.05.027_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.027_bib12","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.027_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7377","key":"10.1016\/j.hoc.2026.05.027_bib14","first-page":"480","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.027_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2026.05.027_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2019.10.033","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials","volume":"125","author":"Hauschild","year":"2020","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.027_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.027_bib18","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2026.05.027_bib19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2026.05.027_bib20","first-page":"371","article-title":"Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.027_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.027_bib22","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation\u21d3positive advanced melanoma: Extended follow-up of the coBRIM study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9992","key":"10.1016\/j.hoc.2026.05.027_bib23","first-page":"386","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.027_bib24","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2026.05.027_bib25","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.027_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jid.2017.07.839","article-title":"STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network","volume":"138","author":"Delyon","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"14","key":"10.1016\/j.hoc.2026.05.027_bib27","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.027_bib28","first-page":"6893","article-title":"Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma","volume":"35","author":"Decoster","year":"2015","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.027_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-015-0330-z","article-title":"Treatment of NRAS-mutant melanoma","volume":"16","author":"Johnson","year":"2015","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.027_bib30","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-17-0723","article-title":"Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na\u00efve and Previously Treated Basal Cell Carcinoma","volume":"24","author":"Bendell","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.027_bib31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.027_bib32","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.027_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1078-0432.CCR-13-1411","article-title":"Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long- term Follow-up","volume":"20","author":"Ugurel","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.027_bib34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-15-1243","article-title":"Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans(DFSP)","volume":"22","author":"Stacchiotti","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.027_bib35","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.027_bib36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2026.05.027_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.027_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.027_bib39","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.027_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.027_bib41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.027_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.027_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw379.02","article-title":"Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma","volume":"27","author":"Hamid","year":"2016","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2026.05.027_bib44","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"10105","key":"10.1016\/j.hoc.2026.05.027_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.027_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.027_bib47","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.hoc.2026.05.027_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.027_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.027_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.027_bib51","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.027_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.027_bib53","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.027_bib54","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221083052","article-title":"Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials","author":"Witt","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.027_bib55","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.027_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.027_bib57","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.027_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.027_bib59","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.027_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9501","article-title":"Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma","volume":"40","author":"Blank","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2026.05.027_bib61","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"6257","key":"10.1016\/j.hoc.2026.05.027_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.hoc.2026.05.027_bib63","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-0458","article-title":"Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis","volume":"26","author":"Osipov","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"33","key":"10.1016\/j.hoc.2026.05.027_bib64","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5950","article-title":"Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice","volume":"6","author":"Campesato","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.027_bib65","doi-asserted-by":"crossref","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.027_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.027_bib67","first-page":"220","article-title":"IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","author":"Reijers","year":"2023","journal-title":"J Exp Med"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.027_bib68","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.027_bib69","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1\u2013based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.027_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.027_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nu\u00f1ez","year":"2023","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.027_bib72","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04172-w","article-title":"Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens","volume":"21","author":"Shen","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.hoc.2026.05.027_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051629","article-title":"Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events","author":"Les","year":"2023","journal-title":"Cancer (Basal)"},{"issue":"10240","key":"10.1016\/j.hoc.2026.05.027_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.027_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.027_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.027_bib77","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-017-6266-8","article-title":"Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology","volume":"25","author":"Crompton","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2026.05.027_bib78","doi-asserted-by":"crossref","DOI":"10.1097\/PPO.0000000000000608","article-title":"Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy","author":"Mullinax","year":"2022","journal-title":"Cancer J"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.027_bib79","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.138.3.989","article-title":"Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma","volume":"138","author":"Muul","year":"1987","journal-title":"J Immunol"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.027_bib80","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.027_bib81","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2026.05.027_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(89)91609-7","article-title":"Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer","author":"Kradin","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2026.05.027_bib83","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","author":"Rosenberg","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2026.05.027_bib84","doi-asserted-by":"crossref","DOI":"10.1097\/00002371-200205000-00007","article-title":"A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma","author":"Dudley","year":"2002","journal-title":"J Immunother"},{"key":"10.1016\/j.hoc.2026.05.027_bib85","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.hoc.2026.05.027_bib86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.027_bib87","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.027_bib88","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","author":"Pilon-Thomas","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.hoc.2026.05.027_bib89","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.027_bib90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.027_bib91","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2518","article-title":"Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1","volume":"37","author":"Sarnaik","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.027_bib92","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-1171","article-title":"Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma","volume":"27","author":"Seitter","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.hoc.2026.05.027_bib93","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen Identification and Response to Adoptive Cell Transfer in Anti\u2013PD-1 Na\u00efve and Experienced Patients with Metastatic Melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.027_bib94","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.hoc.2026.05.027_bib95","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.027_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"Journal for immunotherapy of cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:03:04Z","timestamp":1788390184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000699"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.027","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Oncology in Melanoma and Skin Cancer Surgery","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}